KRAS and cancer: Direct KRASG12C inhibitors undoubtedly represent a major leap forward for the treatment of KRAS-mutant cancers; however, a predicted challenge to their clinical development is the high degree of biological heterogeneity in these tumors, which is likely to affect therapeutic response to KRAS inhibition.